Torcetrapib/atorvastatin

Drug Profile

Torcetrapib/atorvastatin

Alternative Names: Atorvastatin/torcetrapib

Latest Information Update: 05 Dec 2006

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrroles; Quinolines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary disorders; Hyperlipidaemia; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol

Most Recent Events

  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in United Kingdom (PO)
  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in Sweden (PO)
  • 02 Dec 2006 Discontinued - Phase-III for Coronary disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top